{"cmr":"hk-cm-kg/HKEX/02696","since":null,"total":120,"cursor":0,"limit":50,"next_cursor":50,"events":[{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-11-04","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - THE PHASE 1 CLINICAL TRIAL OF HLX109 INJECTION (A MONOCLONAL ANTIBODY TARGETING IL1RAP) FOR THE TREATMENT OF GENERALIZED PUSTULAR PSORIASIS HAS BEEN APPROVED TO COMMENCE IN AUSTRALIA","reference":"12399090","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1104/2026110400504.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"16:30","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"h2VEkEecyAU_JUmUgLKP2JTsw1HcoxAhWohrbyCDbsUzfzw-y-wxhdVnjmSVUfDWpRKxELZRZKAUboCchQdYCg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-11-03","event_type":"monthly_return","title":"Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026","reference":"12397555","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1103/2026110301656.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Monthly Returns","time_hkt":"17:50","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"n_mGfH3oXV_AC_OZQxlv-cgWgr7bsXuj6J_vN-LkPSKDMwGGPgvEZBGJsD1IB44SYZ8SUmyVpF8H171Q6ZzzCg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-11-02","event_type":"documents_on_display","title":"Documents on Display - CONTINUING CONNECTED TRANSACTION - REVISION OF ANNUAL CAP FOR THE COLLABORATION ARRANGEMENTS UNDER THE HLX01 AGREEMENT","reference":"12394006","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1102/2026110202151.htm","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Documents on Display","time_hkt":"16:59","file_type":"HTML","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"1c7RF4huNF1aDTsgHTSaCvGKLWglxXLk3xi4yjmq_u7rhYZcO6a81amnWhuHr6dShKHMVSLROeRKWpHl14bwAg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-11-02","event_type":"agm_egm","title":"PROXY FORM FOR THE 2026 FIRST EXTRAORDINARY GENERAL MEETING TO BE HELD ON MONDAY, 23 NOVEMBER 2026 (OR ANY ADJOURNMENT THEREOF)","reference":"12393748","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1102/2026110201892.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Proxy Forms","time_hkt":"16:45","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"P96YnvHjK3BuftxqnLPMc_g-yEothlimPiT9vCUn3U-QpQg2XCtpH6Qd85AqTjVu0XQs-SCmS3Zq16-COAmLBg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-11-02","event_type":"agm_egm","title":"NOTICE OF EXTRAORDINARY GENERAL MEETING","reference":"12393552","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1102/2026110201696.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Notice of EGM/SGM / Closure of Books or Change of Book Closure Period]","time_hkt":"16:38","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"sPB_AhpfufCZepWOYeRNNAZ_PioiNVKU5tJmQdad1S3naldce9E0cdFeEBKiii3z-uqabKXwFDjSx-IyHeR5Dw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-11-02","event_type":"circular","title":"(1) CONTINUING CONNECTED TRANSACTION REVISION OF ANNUAL CAP FOR THE COLLABORATION ARRANGEMENTS UNDER THE HLX01 AGREEMENT (2) PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND INDEPENDENT NON-EXECUTIVE DIRECTOR AND NOTICE OF EXTRAORDINARY GENERAL MEETING","reference":"12393184","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1102/2026110201328.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Circulars - [Continuing Connected Transaction / Re-election or Appointment of Director subject to Shareholders' Approval]","time_hkt":"16:30","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"xd2wNXQThHGWhOPnsJoONT0Bu4xL7XJsbMeqmBRzUgVeGhY-V48o_Ki1UMLCQM9b4f5WWobekFnGwEc-nXJPCw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-10-27","event_type":"announcement","title":"CONTINUING CONNECTED TRANSACTION - REVISION OF ANNUAL CAP FOR THE COLLABORATION ARRANGEMENTS UNDER THE HLX01 AGREEMENT","reference":"12384845","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1027/2026102701109.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Continuing Connected Transaction]","time_hkt":"20:20","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"Emsp0PU51YwIK1PQ0xZyML3eXUfJR95sOavOe37NUHwbAqeMXj2rLDYVAWROJPCaAplz2UBsJwG4NgFFIIL1BA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-10-06","event_type":"monthly_return","title":"Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026","reference":"12363735","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1006/2026100600969.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Monthly Returns","time_hkt":"17:17","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"0lmosEKclH7Rl3k6W3HnktEibNHDVYjqSEAeM1aHNqvMx8HBlUCBzOnLEBX5NviXiL9XnhP9-Ia1fZjEbBKzBA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-09-30","event_type":"announcement","title":"LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS","reference":"12353154","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0930/2026093001284.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [List of Directors and their Role and Function]","time_hkt":"17:13","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"rHLfvAtf1t2OCgkC5vAFhj2EMPFDrHgvGsTSsviIPBknOAszD5hacdvfgamOFsh47AOyZGvPV9r79bBDwKtMDw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-09-30","event_type":"director_change","title":"(1) CHANGES IN NON-EXECUTIVE DIRECTOR AND INDEPENDENT NON-EXECUTIVE DIRECTOR (2) APPOINTMENT OF CHAIRMAN OF THE BOARD AND CHANGES IN COMPOSITION OF THE BOARD COMMITTEES","reference":"12353115","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0930/2026093001245.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Re-election or Appointment of Director subject to Shareholders' Approval / Change in Directors or of Important Executive Functions or Responsibilities / Change of Nomination Committee Member]","time_hkt":"17:10","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"MVlfts0L9IktNSCEAl3RxIAKSND0r-nZQ_2q-Xf0I7vETsf4MzrdLen3GzoawfWX2INYieyhDarWl_hv_pgZBg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-09-24","event_type":"interim_report","title":"INTERIM REPORT 2026","reference":"12344962","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0924/2026092400807.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Financial Statements/ESG Information - [Interim/Half-Year Report]","time_hkt":"16:53","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"G6wtb-NzlqL-0Vf9_J5xmfY90hXpThsCKHuyptTwXlSYtPaRZsiQacXnikQ1IPL6Wg3EluWy4mH-XCtqtviWAw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-09-23","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - COLLABORATION AND LICENSE AGREEMENT WITH AMBERSTONE FOR TWO T CELL ENGAGER PRODUCTS","reference":"12342803","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0923/2026092300674.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"16:58","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"IaWB4d_qf_Q5qPsKs4eqvK6UNjAh9tA4BhL1Rnz9tAllYXd3_QDWxayrSHm8R5vLR0iZitwyRz_PiOHhqwQmBQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-09-11","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) FOR 120 MG (1.7 ML) PER VIAL STRENGTH OF BIOSIMILAR OF DENOSUMAB HLX14 (RECOMBINANT ANTI-RANKL HUMAN MONOCLONAL ANTIBODY INJECTION) HAS BEEN ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA)","reference":"12328894","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0911/2026091100302.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"16:30","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"LeB1s8zLc7_lQ3izIHdeDnLC66_7Wlg20hGtVG-KZjdUi0WJ8K1X7r7i3BR2dSmj_zsAoJUSTWa3QA45i3-TBQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-09-07","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - INCLUSION IN THE LIST OF ELIGIBLE SECURITIES OF HONG KONG STOCK CONNECT","reference":"12322726","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0907/2026090700185.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Miscellaneous]","time_hkt":"12:00","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"AfunB9ZSgwo5LoOUdsTgZu36rFaJVk4xindvf-GLxAJFioNuZPGg1nPdAKb-kHm7yiK-IytP5TnD2iGAwWxlAg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-09-02","event_type":"monthly_return","title":"Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2026","reference":"12316275","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0902/2026090201670.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Monthly Returns","time_hkt":"17:38","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"Rrgmy71WlZoyZiAn_Fp8MJ-os3y8Y7_fXXoU61r4u8gq7y7H99Zc90VKoMApd5T4X0Lfhon6q3au7-gFJZX8Aw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-08-25","event_type":"next_day_disclosure","title":"Next Day Disclosure Returns","reference":"12298248","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0825/2026082501089.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Next Day Disclosure Returns - [Others]","time_hkt":"18:24","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"rX7Qm9oHWCjTzSCFz2gCLguAkzsxIp5SNXLaQgt27VHWpmwWRYscyWx8sGX7OZcZfjosUTQWR2QgRsrtiL0ODA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-08-21","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE COMPANY AS A CONSTITUENT STOCK OF HANG SENG COMPOSITE INDEX","reference":"12294618","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0821/2026082101181.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Miscellaneous]","time_hkt":"19:31","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"3O_FPndcGRywfzMvb46nBtmKs_seuj_scsylHnfijYaT7nwH7dM5RrJS5-ut2KxTN9iJuWW19H23s3XOevp5AQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-08-21","event_type":"results","title":"INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026 AND CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG","reference":"12294586","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0821/2026082101149.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Interim Results / Change in Registered Address or Office, Registered Place of Business in HK or Agent for Service of Process in HK]","time_hkt":"19:24","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"ut9Mqao4wuXcQgyk_g1g0VqZRFlwWLzlQ-bk-wTpNk2YKsB47aYpUkqZ5PUJfYL__Uw_3N9BT28WSeS9vejuBg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-08-17","event_type":"announcement","title":"INSIDE INFORMATION ANNOUNCEMENT - STRATEGIC COLLABORATION WITH SANDOZ","reference":"12285867","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081700129.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Inside Information]","time_hkt":"08:00","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"d0GBxFcKS4EifgSFnvnfQcRtLpE2YSQR2zNJua8dOD24FovbRLANaghtmfz4aIK4-pusooMKIU8EEBw_U711Dw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-08-04","event_type":"monthly_return","title":"Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2026","reference":"12270915","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0804/2026080401101.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Monthly Returns","time_hkt":"16:54","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"wb0qbMs32L1Jphry4Stj99RBueU2Yq3tbMgj60woNKN-K_IfbOW_yCUfG47jLQxo-W6oT_Ey7vAsCyhyIcLBCg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-08-03","event_type":"agm_egm","title":"DATE OF BOARD MEETING","reference":"12268012","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0803/2026080302236.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Date of Board Meeting]","time_hkt":"17:00","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"7bWmzIlOf1ZVNZ9Vy6EIrkh-v1mq79eOVYnivkp9OVlJ4dhOEHsM23sYXFeYHFKZyvVCq8eflWv8xhLa-8-JDA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-07-31","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION FOR CLINICAL TRIAL OF HLX43 FOR INJECTION (AN ANTIBODY-DRUG CONJUGATE TARGETING PD-L1) IN COMBINATION WITH BEVACIZUMAB WITH OR WITHOUT CHEMOTHERAPY FOR THE TREATMENT OF ADVANCED/METASTATIC SOLID TUMOURS HAS BEEN APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION","reference":"12263539","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0731/2026073100326.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"16:30","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"ITb_zWUcmCtS8oO0g89dihNk7v2vEJVTp9z-dHnW9g1j5fa3EyuUM-uisw4DeKHCisIHWz-rNRuN5sTtMJGRCA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-07-30","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX3902 INJECTION (STEAP1xCD3xCD28 TRISPECIFIC ANTIBODY) FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER ADVANCED SOLID TUMORS IN CHINESE MAINLAND","reference":"12261965","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0730/2026073000930.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"17:25","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"zPjio0DfQgUtMnbnEbmZs6i7EqUCLMiFDXFHdN00RblT4OFNUw-WWlsT9AFCUFjHFka3NUc2KyCb7FjVtlM6DA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-07-17","event_type":"announcement","title":"GRANTS OF OPTIONS AND RSUS","reference":"12248876","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0717/2026071701565.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Share Scheme]","time_hkt":"22:26","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"1fuwXzQ_o0Sd8HgmnFg1_dPxbzXByBjIeehRBQm-LFNFw1RiGCSNRhmZjGycMs8bSMGUEdFIStTEtLRfsbguAw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-07-16","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - THE GLOBAL FIRST PATIENT HAS BEEN DOSED IN AN INTERNATIONAL MULTI-CENTER PHASE 1 CLINICAL STUDY OF NIVOLUMAB BIOSIMILAR HLX18 (RECOMBINANT ANTI-PD-1 HUMANIZED MONOCLONAL ANTIBODY INJECTION) IN PATIENTS WITH MULTIPLE RESECTED SOLID TUMORS IN CHINESE MAINLAND","reference":"12246352","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0716/2026071600215.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"16:30","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"bKRWT-3cZhdu7VwJyZdosYEJF223z0LLqcpUP4HuLyqlIyaRv1_AUWhVRSRgi-iri3absBfvn32DA0sUNTkWDg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-07-10","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION FOR THE PHASE 1 CLINICAL TRIAL OF HLX37 (RECOMBINANT HUMANISED ANTI-PD-L1 AND ANTI-VEGF BISPECIFIC ANTIBODY) IN COMBINATION WITH CHEMOTHERAPY OR HLX43 FOR INJECTION (AN ANTI-PD-L1 ANTIBODY-DRUG CONJUGATE) FOR THE TREATMENT OF ADVANCED/METASTATIC SOLID TUMOURS HAS BEEN APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION","reference":"12240689","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0710/2026071000245.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"16:30","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"iYMuZ5h_-n6lbyy2WD_uxf5ko3mlheSSk1fTTlt7sLmurNPyl90KolE2jQ7Rr7ABi7RT6G8Z_I6OnXs3erUyAg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-07-08","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF CETUXIMAB INJECTION BIOSIMILAR HLX05-N (RECOMBINANT ANTI-EGFR CHIMERIC HUMAN-MURINE MONOCLONAL ANTIBODY INJECTION) IN PATIENTS WITH METASTATIC COLORECTAL CANCER (mCRC) IN CHINESE MAINLAND","reference":"12237826","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0708/2026070800517.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"17:24","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"PZQN3lKX9LLjrFDAoMJAmuVLQ5RN7o-taQYQJ5wgaWibkU0n3y3UMC30zXWo12F7G2a6tUJF_ehDAoZAqi_HDQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-07-06","event_type":"monthly_return","title":"Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2026","reference":"12234086","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0706/2026070601020.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Monthly Returns","time_hkt":"17:11","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"aFHR7isnwrCxzhebT5T2gY_anC17w3A6Q-uCugPC0zbQhl1UDxQKyU7exd0urG2aOf6c0Y6Pvj6JiGINaXWhDw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-06-30","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX48 FOR INJECTION (AN ANTIBODY-DRUG CONJUGATE TARGETING EGFR AND C-MET) FOR THE TREATMENT OF ADVANCED/ METASTATIC SOLID TUMORS IN CHINESE MAINLAND","reference":"12222459","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063001292.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"17:14","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"57WjovAsebSSAADkNPuMxQQw_GiVUiqOXtG1zZzWuxcR7MmFGp2k3ZFys2jficfbDRnvlcW_CIHT9vFNaif0Cg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-06-25","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT IN THE UNITED STATES HAS BEEN DOSED IN AN INTERNATIONAL MULTICENTER PHASE 1 CLINICAL STUDY OF IPILIMUMAB BIOSIMILAR HLX13 (RECOMBINANT ANTI-CTLA-4 FULLY HUMAN MONOCLONAL ANTIBODY INJECTION) AS A FIRST-LINE TREATMENT FOR PATIENTS WITH UNRESECTABLE ADVANCED HEPATOCELLULAR CARCINOMA (HCC)","reference":"12215212","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0625/2026062501162.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"18:20","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"R9IvZNNfC4hcsJhwvGOFKRz38vhs51MRxCBGg1YsndYYfo86nYljzLPLmz6684IfbEgJNtEzrhHACxbDH1knCw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-06-25","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - THE EUROPEAN COMMISSION (EC) HAS APPROVED A NEW INDICATION FOR SERPLULIMAB INJECTION (TRADE NAME IN CHINESE MAINLAND: HANSIZHUANG; TRADE NAME IN THE EUROPEAN UNION: HETRONIFLY), IN COMBINATION WITH CHEMOTHERAPY INDICATED FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC SQUAMOUS NON-SMALL CELL LUNG CARCINOMA (sqNSCLC)","reference":"12215132","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0625/2026062501082.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"18:02","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"ko-WlY3zwTuR62z850_BZW0MM2L8yFv6aNJ4Vn5Ij392PgWmznXuY8oZ2STHvfhE8Wo8M3TshDKwYSg5MgfvAg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-06-17","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - THE PHASE 1 CLINICAL TRIAL OF HLX3902 INJECTION (STEAP1xCD3xCD28 TRISPECIFIC ANTIBODY) FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER ADVANCED SOLID TUMORS HAS BEEN APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION","reference":"12206337","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0617/2026061700916.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"17:18","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"LK4szFQUUbTntSrSDNZu8eC1GfFthuccur6YTvsw0779WciyqQA1tXbrjzLENRakHEIjx2gYHhvErszfZ1TWDQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-06-17","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - HANBEIYOU (PERTUZUMAB INJECTION) PASSING GMP COMPLIANCE INSPECTION","reference":"12206277","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0617/2026061700852.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"17:11","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"XsG9VoUayyJvWwaGUxz-ov478DhZpf_1ddiUrXfonFNCAvnPQAzjBBsjjbVlQhHQao-Pz2i5qp22yM6QCJ6dCA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-06-16","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - THE PHASE 2 CLINICAL TRIAL OF HLX43 FOR INJECTION (AN ANTI-PD-L1 ANTIBODY-DRUG CONJUGATE) IN COMBINATION WITH HANSIZHUANG (SERPLULIMAB INJECTION) FOR NEOADJUVANT THERAPY OF NON-SMALL CELL LUNG CANCER (NSCLC) APPROVED TO COMMENCE IN AUSTRALIA","reference":"12204832","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0616/2026061600910.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"17:14","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"RFeoEA_nnitt6kXrHoG0FK05tnYJKlmznQ7_P_N1XYpXSf36lW_4z6VOedv-UTqqkSfFKnyJYlurN2037SdjBA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-06-16","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - AN INTERNATIONAL MULTI-CENTER PHASE 3 CLINICAL STUDY OF RECOMBINANT ANTI-VEGF HUMANISED MONOCLONAL ANTIBODY INJECTION HLX04-O FOR THE TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION (wAMD) HAS MET THE PRIMARY STUDY ENDPOINT","reference":"12204754","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0616/2026061600760.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"17:00","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"JLheB6Ov65AtjZu4oDujk3qUcoBxC7UMWYVngMX3w0Gb5NX1ihrjBvDWaWctCZjr1Q2wlGnY1CKNCnu01uckAA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-06-11","event_type":"next_day_disclosure","title":"Next Day Disclosure Returns","reference":"12199293","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0611/2026061100793.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Next Day Disclosure Returns - [Others]","time_hkt":"17:27","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"IleePBJQgqj5orpjAumBZ6LowkARy0T0SJ8zdN4ECWY-ztv0OdLZRsGuL9nmIdosrk7mvOFaJ9DePiN2wPl3DA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-06-09","event_type":"announcement","title":"INSIDE INFORMATION ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) FOR NEW INDICATION OF HANSIZHUANG (SERPLULIMAB INJECTION) IN COMBINATION WITH CHEMOTHERAPY FOR NEO-/ADJUVANT TREATMENT FOR GASTRIC CANCER HAS BEEN APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA)","reference":"12196396","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0609/2026060900923.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Inside Information]","time_hkt":"18:09","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"_TTx72Cn0FSRkqkGgJ10f--UlNp5i6b8Cw1VBXwqEvVf2rOfBKFteUvjLptWb96wURASZWBq3wb709ML1x9iAQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-06-05","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN AN INTERNATIONAL MULTI-CENTER PHASE 1 CLINICAL STUDY OF A BIOSIMILAR OF PEMBROLIZUMAB HLX17 (RECOMBINANT HUMANISED ANTI-PD-1 MONOCLONAL ANTIBODY INJECTION) IN PATIENTS WITH MULTIPLE RESECTED SOLID TUMOURS IN THE UNITED STATES","reference":"12191811","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0605/2026060500397.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"16:30","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"5O4X0FZ516Vu2frCAObnX1BIrBVkh52dyX1kiigjYpc5V4HicRq0U5_l0hdFLCY71YIh4XWCMdvnRvi238O7Cg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-06-03","event_type":"monthly_return","title":"Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2026","reference":"12186606","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0603/2026060301080.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Monthly Returns","time_hkt":"16:54","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"LPMA1rQj2fELPizLZw7pQVCyajjh0pp3EyV7BPunwBFuPzKm3hj0jvqnHgqIDGoL6XvIiuwsu7qkPzDBj2t1Cg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-05-29","event_type":"announcement","title":"INSIDE INFORMATION ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVED HANBEIYOU (PERTUZUMAB INJECTION) FOR THE NEOADJUVANT/ADJUVANT TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER AND FOR THE TREATMENT OF METASTATIC BREAST CANCER","reference":"12176410","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0529/2026052900666.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Inside Information]","time_hkt":"16:30","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"Oq3DPCOvHRZUNilm9Y1vQDkuprS68Vlwj0PWrBFAR366W9yekO_9A3A-N2kldaf5iR0WqHXqxdPUViX1rYV2Ag","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-05-28","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN AN INTERNATIONAL MULTICENTRE PHASE 2/3 CLINICAL STUDY OF HLX43 FOR INJECTION (AN ANTI-PD-L1 ANTIBODY-DRUG CONJUGATE) AS MONOTHERAPY OR IN COMBINATION WITH PIMURUTAMAB HLX07 (RECOMBINANT ANTI-EGFR HUMANIZED MONOCLONAL ANTIBODY INJECTION) VERSUS DOCETAXEL FOR THE TREATMENT OF ADVANCED/METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE PRIOR TREATMENT HAS FAILED IN CHINESE MAINLAND","reference":"12174089","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0528/2026052800515.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"16:30","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"YUXF-g8ymYwUgB0mVOOEAo1MmAQl7sc-6uNs0a8BB81ln3jlTkSgbrFSLoxnSwuE6zT8Dik1rxKyinBxECTRCw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-05-26","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN AN INTERNATIONAL MULTICENTER PHASE 2/3 CLINICAL STUDY COMPARING PIMURTAMAB HLX07 (RECOMBINANT ANTI-EGFR HUMANIZED MONOCLONAL ANTIBODY INJECTION) IN COMBINATION WITH HANSIZHUANG (SERPLULIMAB INJECTION) AND CHEMOTHERAPY VERSUS PLACEBO IN COMBINATION WITH HANSIZHUANG (SERPLULIMAB INJECTION) OR PEMBROLIZUMAB AND CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF ADVANCED SQUAMOUS NON-SMALL CELL LUNG CANCER (SQNSCLC) IN CHINESE MAINLAND","reference":"12170652","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0526/2026052600652.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"16:59","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"ZrHpgxRREnRLJCypiRyd-NuVSX-5gp6FPPc0KT-_xm4BrcW3cidx-W12zbOCDBkb2GgaCad2tUXZQpHCIsCGCA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-05-26","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN AN INTERNATIONAL MULTICENTER PHASE 1 CLINICAL STUDY OF HLX15-SC (RECOMBINANT ANTI-CD38 FULLY HUMAN MONOCLONAL ANTIBODY INJECTION-SUBCUTANEOUS INJECTION) FOR FIRST-LINE TREATMENT OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) IN CHINESE MAINLAND","reference":"12170616","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0526/2026052600616.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"16:51","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"f7VoaqUT0I_0UM0zpW20VR3cfhr4tStAOZO-Ceadp0dKs-SMWpFV3LfkhEA7zqFfdqQmdPAha7IwxTqk4qKuBw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-05-22","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - SERPLULIMAB INJECTION (TRADE NAME IN CHINESE MAINLAND: HANSIZHUANG; TRADE NAME IN THE EUROPEAN UNION: HETRONIFLY) RECEIVED POSITIVE OPINION FROM THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OF THE EUROPEAN MEDICINES AGENCY (EMA)","reference":"12169585","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0522/2026052201798.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"21:47","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"-XqGDhM1ESp7oIqBwL6vJU4fna5vGXZLMmri1sFcrn8wXsxConLpWEDy2icyIEQAyfH3C9IhWynUYE8MrvaPBw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-05-22","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX316 FOR INJECTION (B7-H3-TARGETING SIALIDASE FC FUSION PROTEIN) IN PATIENTS WITH ADVANCED/METASTATIC SOLID TUMOURS IN CHINESE MAINLAND","reference":"12168287","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0522/2026052200468.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"16:44","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"Q-wdQI4QdAIZU5j47wlmH7QJ8lqHeCxVu86UTYH2Vxqu5Wy8PH2IlppPxeSQnRGCf2rwm8BQPr-Tk9DORciJCA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-05-21","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT IN AN EU COUNTRY (SPAIN) HAS BEEN DOSED IN AN INTERNATIONAL MULTICENTRE PHASE 2 CLINICAL STUDY OF HLX43 FOR INJECTION (AN ANTI-PD-L1 ANTIBODY-DRUG CONJUGATE) FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)","reference":"12166689","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0521/2026052100732.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"17:30","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"ms2seLHimbCCJ16nahgE7X0pybdmsgTE346kgPIacXJClrlr-vyErPkHi_NnFS30ZWRvCuaYaVJae8x8UFJSBw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-05-21","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - THE PHASE 1 CLINICAL TRIAL OF HLX3902 INJECTION (STEAP1xCD3xCD28 TRISPECIFIC ANTIBODY) FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER ADVANCED SOLID TUMORS HAS BEEN APPROVED TO COMMENCE IN AUSTRALIA","reference":"12166632","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0521/2026052100675.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"17:22","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"I8AWDZXGgwTd4TasAP7FzKM7BE1XG7j0bG7CDF_GOQEWJOiNnPzqpH8Dp0Dln-2_L_iBJfVkMO6iDt7Ra_8IAg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-05-21","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION FOR THE PHASE 1 CLINICAL TRIAL OF HLX48 FOR INJECTION (AN ANTIBODY-DRUG CONJUGATE TARGETING EGFR AND C-MET) FOR THE TREATMENT OF ADVANCED/METASTATIC SOLID TUMORS HAS BEEN APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION","reference":"12166588","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0521/2026052100631.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"17:13","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"D97fbZXTG0HlE-fSLvp_LROwJrWoCd8GzLD-pajOqxFGyJhptsG32wZA7ElzwJj8c9-OFzu9LqG-gBuYlPLSAw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-05-19","event_type":"agm_egm","title":"POLL RESULTS OF THE RESOLUTIONS PROPOSED AT THE ANNUAL GENERAL MEETING HELD ON TUESDAY, 19 MAY 2026","reference":"12163986","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0519/2026051900821.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Results of AGM]","time_hkt":"18:31","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"N2_lhMAKrjGNk5RYFbxZyfFTNNcKCwAvsmBr5Er9YHkeryRsjI6ZCKEXC8YcqExUGhy-noT4FUgqZif4TKf7Cw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"hk-cm-kg/HKEX/02696","date":"2026-05-13","event_type":"announcement","title":"VOLUNTARY ANNOUNCEMENT - THE PHASE 1 CLINICAL TRIAL OF HLX48 FOR INJECTION (AN ANTIBODY-DRUG CONJUGATE TARGETING EGFR AND C-MET) FOR THE TREATMENT OF ADVANCED/METASTATIC SOLID TUMORS HAS BEEN APPROVED TO COMMENCE IN AUSTRALIA","reference":"12157414","wire":"HKEXnews","source":"HKEXnews (listed company information, title search)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0513/2026051300522.pdf","read_by":"HKEXnews title search (titleSearchServlet.do, lang=E)","state":"sourced","hkex_category":"Announcements and Notices - [Other - Business Update]","time_hkt":"17:07","file_type":"PDF","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"2P6l8Wts70SyJusSqF75GDgjXXi9AF0JjHFjbEuhOb_g3Mb0oyuk_L96Qh1Teu14T565pWp2z5Q1DLSIEYU2Bg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}}],"events_signed":"allooloo-cmr-2026-10"}